Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Merck
Chubb
Medtronic
US Department of Justice
Harvard Business School
McKinsey
Johnson and Johnson
UBS
Novartis

Generated: January 21, 2018

DrugPatentWatch Database Preview

BANZEL Drug Profile

« Back to Dashboard

When do Banzel patents expire, and when can generic versions of Banzel launch?

Banzel is a drug marketed by Eisai Inc and is included in two NDAs. There are three patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in BANZEL is rufinamide. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rufinamide profile page.

US Patents and Regulatory Information for BANZEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc BANZEL rufinamide SUSPENSION;ORAL 201367-001 Mar 3, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-002 Nov 14, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-001 Nov 14, 2008 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-002 Nov 14, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Eisai Inc BANZEL rufinamide SUSPENSION;ORAL 201367-001 Mar 3, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-001 Nov 14, 2008 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-002 Nov 14, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-001 Nov 14, 2008 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-003 Nov 14, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-003 Nov 14, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BANZEL
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 100 mg, 200 mg and 400 mg ➤ Subscribe 11/14/2012
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 6/16/2014

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Dow
Moodys
Queensland Health
Cantor Fitzgerald
Colorcon
Federal Trade Commission
Harvard Business School
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot